Hsbc Holdings PLC Has $1.23 Million Stake in Astrazeneca Plc $AZN

Hsbc Holdings PLC decreased its holdings in Astrazeneca Plc (NYSE:AZN) by 94.4% in the 1st quarter, HoldingsChannel reports. The firm owned 6,297 shares of the company’s stock after selling 106,968 shares during the quarter. Hsbc Holdings PLC’s holdings in Astrazeneca were worth $1,227,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Whipplewood Advisors LLC boosted its stake in Astrazeneca by 1,093.8% during the 1st quarter. Whipplewood Advisors LLC now owns 955 shares of the company’s stock worth $188,000 after acquiring an additional 875 shares during the last quarter. Channing Global Advisors LLC increased its holdings in shares of Astrazeneca by 1,469.2% during the 1st quarter. Channing Global Advisors LLC now owns 167,622 shares of the company’s stock worth $32,489,000 after acquiring an additional 156,940 shares during the last quarter. Mitsubishi UFJ Morgan Stanley Securities Co. Ltd. bought a new position in Astrazeneca during the first quarter worth $202,000. Credit Industriel ET Commercial acquired a new position in shares of Astrazeneca in the first quarter valued at $288,000. Finally, Kiley Juergens Wealth Management LLC bought a new position in shares of Astrazeneca in the first quarter valued at about $394,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Key Astrazeneca News

Here are the key news stories impacting Astrazeneca this week:

• Positive Sentiment: Profit beat and outlook maintained: Second-quarter earnings were $2.63 per share, well above the $2.10 analyst consensus. AstraZeneca also backed its 2026 forecasts, helping ease concerns about longer-term growth. AstraZeneca beats second-quarter profit expectations, holds outlook
• Positive Sentiment: Oncology and rare-disease demand remained strong: Growth from cancer, heart-disease and rare-disease therapies helped offset weaker sales in other products and increasing generic competition. First-half revenue rose 9% to $30.7 billion, or 6% at constant exchange rates. AZN Q2 Earnings and Sales Beat, Key Drugs Offset Generic Pressure
• Neutral Sentiment: Revenue slightly missed expectations: Quarterly revenue increased 6.4% year over year to $15.38 billion, narrowly below the $15.44 billion analyst estimate. Management is also navigating weaker conditions in China and the loss of exclusivity for certain products. AstraZeneca Q2 2026 Earnings Call Highlights
• Negative Sentiment: Pipeline setback: Ultomiris failed to meet the main goal in a late-stage trial involving a blood-vessel complication after stem-cell transplantation. The result adds to recent concerns about AstraZeneca’s development pipeline, although the company’s established portfolio supported the quarter. AstraZeneca’s rare disease drug misses main goal in late-stage trial
• Negative Sentiment: U.S. pricing pressure remains a risk: AstraZeneca is adjusting pricing strategies for new medicines in response to the Trump administration’s most-favoured-nation policy, which could constrain future pricing and margins in the U.S. AstraZeneca drug prices evolving in response to Trump policy

Analysts Set New Price Targets

Several analysts recently commented on the stock. Sanford C. Bernstein reaffirmed a “buy” rating on shares of Astrazeneca in a report on Monday, May 4th. Weiss Ratings cut Astrazeneca from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, June 18th. UBS Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a report on Friday, June 26th. Finally, Barclays reaffirmed a “buy” rating on shares of Astrazeneca in a report on Monday, June 1st. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $211.00.

Astrazeneca Stock Performance

NYSE AZN opened at $170.02 on Tuesday. The firm’s fifty day moving average price is $180.27 and its two-hundred day moving average price is $187.99. The stock has a market cap of $263.68 billion, a PE ratio of 25.53, a PEG ratio of 1.38 and a beta of 0.24. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91. Astrazeneca Plc has a fifty-two week low of $142.98 and a fifty-two week high of $212.71.

Astrazeneca (NYSE:AZN) last announced its quarterly earnings results on Monday, July 27th. The company reported $2.63 EPS for the quarter, beating analysts’ consensus estimates of $2.50 by $0.13. The company had revenue of $15.38 billion during the quarter, compared to analysts’ expectations of $15.44 billion. Astrazeneca had a return on equity of 30.86% and a net margin of 17.19%.Astrazeneca’s revenue was up 6.4% compared to the same quarter last year. During the same period in the prior year, the company earned $2.17 EPS. On average, equities analysts expect that Astrazeneca Plc will post 10.22 EPS for the current fiscal year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.